FRC
FRC Logo
Sign InGet Access

Connect With Us

Stay updated with our latest research and insights

Fundamental Research Corp Logo

Highly ranked equity research firm providing institutional grade tools and analysis to all investors worldwide. Trusted by global investors for over 20+ years.

20+ Years

Policies

  • Privacy Policy
  • Terms of Service
  • Disclaimer

Company

  • About Us
  • Our Team
  • Contact Us

Resources

  • Videos
  • Research Reports
  • FAQ

© 2026 Fundamental Research Corp. All Rights Reserved.

Professional investment research since 2003

Home
Research
Get Access
Sign In
ACADIA Pharmaceuticals Inc. Stock AnalysisComprehensive stock analysis for ACADIA Pharmaceuticals Inc. (ACAD) including live price, Snowflake performance metrics, financial statements, and investment research.Stock AnalysisACAD
ACAD
ACADIA Pharmaceuticals Inc.
  • Company Overview
  • FRC Research
  • Financial Data
  • Peer Comparison
  • Ownership & News
ACAD
Home🔹Stocks🔹ACADIA Pharmaceuticals Inc.

ACADIA Pharmaceuticals Inc.

ACAD•NASDAQ

ACADIA Pharmaceuticals Inc.

ACAD•NASDAQ
Market cap
$4.45B
Sentiment

Your view on ACAD

Mkt Cap
$4.45B
Sentiment
Your view
ACAD
ACADIA Pharmaceuticals Inc.
  • Company Overview
  • FRC Research
  • Financial Data
  • Peer Comparison
  • Ownership & News
ACAD
Company Overview

Overview

What the company does, where it operates, and who runs it.

About ACADIA Pharmaceuticals Inc.

Industry
Biotechnology
Sector
Healthcare
CEO
Catherine E. Owen Adams
Headquarters
12830 El Camino Real, San Diego, CA, US
Industry
Biotechnology
Sector
Healthcare
CEO
Catherine E. Owen Adams
Headquarters
12830 El Camino Real, San Diego, CA, US
Description

ACADIA Pharmaceuticals Inc., a biopharmaceutical company, focuses on the development and commercialization of small molecule drugs that address unmet medical needs in central nervous system disorders. The company offers NUPLAZID (pimavanserin) for the treatment of hallucinations and delusions associated with Parkinson's disease psychosis. It's pipeline include, pimavanserin, under phase 3 development for the treatment of Alzheimer's disease psychosis, and negative symptoms of schizophrenia; Trofinetide, a novel synthetic analog, under phase 3 development for the treatment of Rett syndrome; ACP-044, a novel first-in-class orally administered non-opioid analgesic, under phase 2 development for treating acute and chronic pain; and ACP-319, a positive allosteric modulator of the muscarinic receptor, under phase 1 development for treating schizophrenia and cognition in Alzheimer's. ACADIA Pharmaceuticals Inc. was founded in 1993 and is headquartered in San Diego, California.

Infographics

Visual summary of the business at a glance.

FRC Research

Media

Videos and interviews covering the company.

Financial Data

Stock Data

Price chart, volume, and trading data.

Fair Value

What FRC thinks the stock is worth vs. the current price.

Financial Ratios

Profitability, returns, valuation, and leverage ratios.

Dividend Analysis

Yield, payout ratio, and dividend coverage metrics.

Earnings Analysis

EPS history, beat rate, and upcoming earnings reports.

Financial Statements

Income statement, balance sheet, and cash flow statements.

Peer Comparison

Comparables

List of peer companies in the same industry.

Ownership & News

Institutional Ownership

Which funds and firms own the stock.

Insider Trading

Recent buying and selling by company executives.

Senate Trading

U.S. Senator disclosures filed under the STOCK Act.

News

Latest headlines and market coverage.

News

Latest Market News